Therefore, we performed this meta-analysis of randomized trials to evaluate the survival efficacy of MET inhibitors combined with an EGFR TKI or standard chemotherapy in patients with advanced or metastatic NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.